ALK and lung cancer: Molecular targeted therapies such as tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutants and anaplastic lymphoma kinase (ALK) inhibitors in ALK rearranged NSCLC patients have recently advanced the management of lung cancer for a limited proportion of patients (35–39).